Home/Dexcom/Matthew Dolan
MD

Matthew Dolan

EVP, Strategy & Corporate Development

Dexcom

Therapeutic Areas

Dexcom Pipeline

DrugIndicationPhase
Dexcom G7 CGMType 1 and Type 2 DiabetesCommercial
Dexcom G7 15 DayType 1 and Type 2 DiabetesCommercial
Stelo Glucose BiosensorOver-the-counter metabolic health monitoringCommercial